374796-29-9

Basic information

• Product Name: 1-Oxa-9-azaspiro[5.5]undecane-9-carboxylic acid, 4-hydroxy-, 1,1-diMethylethyl ester
• Synonyms: 1-Oxa-9-azaspiro[5.5]undecane-9-carboxylic acid, 4-hydroxy-, 1,1-diMethylethyl ester;4-hydroxy-1-oxa-9-azaspiro[5.5]undecane-9-carboxylic acid tert-butyl ester
• CAS NO: 374796-29-9
• Molecular Formula: C₁₄H₂₅NO₄
• Molecular Weight: 271.3526
• Mol File: 374796-29-9.mol

Chemical Properties

• Boiling Point: 406.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.14±0.1 g/cm3(Predicted)
• PKA: 14.84±0.20(Predicted)
• CAS DataBase Reference: 1-Oxa-9-azaspiro[5.5]undecane-9-carboxylic acid, 4-hydroxy-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Oxa-9-azaspiro[5.5]undecane-9-carboxylic acid, 4-hydroxy-, 1,1-diMethylethyl ester(374796-29-9)
• EPA Substance Registry System: 1-Oxa-9-azaspiro[5.5]undecane-9-carboxylic acid, 4-hydroxy-, 1,1-diMethylethyl ester(374796-29-9)

Safety Data

• Hazardous Substances Data: 374796-29-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Oxa-9-azaspiro[5.5]undecane-9-carboxylic acid, 4-hydroxy-, 1,1-diMethylethyl ester is used as a potential pharmaceutical candidate for its potential antimicrobial, antiproliferative, and antifungal properties. The presence of the 4-hydroxy group and the 1,1-dimethylethyl ester group may enhance its interaction with biological targets, making it a promising compound for further research and development.
Further research and study are required to understand the full range of potential uses and implications of 1-Oxa-9-azaspiro[5.5]undecane-9-carboxylic acid, 4-hydroxy-, 1,1-diMethylethyl ester in the pharmaceutical industry. The unique structure and functional groups of 1-Oxa-9-azaspiro[5.5]undecane-9-carboxylic acid, 4-hydroxy-, 1,1-diMethylethyl ester may offer new opportunities for the development of novel therapeutic agents with improved efficacy and selectivity.

Upstream product

• 374795-40-1 tert-butyl 1-oxa-9-azaspiro[5.5]undec-3-ene-9-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 203662-51-5 1-(t-butoxycarbonyl)-4-(prop-2-enyl)-4-hydroxypiperidine 
• 374795-39-8 tert-butyl 4-allyl-4-(allyloxy)piperidine-1-carboxylate 
• 1785761-76-3 9-benzyl-1-oxa-9-azaspiro[5.5]undecan-4-ol 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 503551-94-8 methanesulfonic acid 9-benzyl-1-oxa-9-azaspiro[5.5]undec-4-yl ester 

Relevant articles and documents

CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF

Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Nitroimidazole compound as well as preparation method and application thereof

The invention discloses a novel nitroimidazole compound as well as a preparation method and application thereof. The nitroimidazole compound has a general formula (I) shown in the specification.

Spirocyclic amino alcohol building blocks prepared via a Prins-type cyclization in aqueous sulfuric acid

A convenient Prins cyclization of various azacycloalkanones with homoallylic alcohol was achieved in aqueous sulfuric acid. The formal four-center, three-component reaction provides a facile and flexible entry into a range of spirocyclic amino alcohols wh

Cyclohexane derivatives and their use as therapeutic agents

The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.